Advisors Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.1K Sell
1,716
-2,275
-57% -$37.2K ﹤0.01% 1385
2026
Q2
$77.7K Buy
3,991
+49
+1% +$888 ﹤0.01% 1261
2026
Q1
$73.5K Sell
3,942
-50
-1% -$828 ﹤0.01% 1265
2025
Q4
$52.6K Sell
3,992
-2
-0.1% -$24 ﹤0.01% 1303
2025
Q3
$28.6K Sell
3,994
-15
-0.4% -$782 ﹤0.01% 1333
2025
Q2
$189K Hold
4,009
– – ﹤0.01% 1124
2025
Q1
$157K Buy
4,009
+1,803
+82% +$77.7K ﹤0.01% 1135
2024
Q4
$119K Buy
+2,206
New +$113K ﹤0.01% 1195

Other funds holding MLTX

Advisors Asset Management's MLTX Position: Q3 2026 in Review

Advisors Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 57% in Q3 2026, selling an estimated $37.2K and leaving 1,716 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

Advisors Asset Management first reported a position in MLTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $189K in Q2 2025. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Advisors Asset Management held 1,716 shares of MoonLake Immunotherapeutics worth $20.1K as of Q3 2026.
  • Advisors Asset Management sold 2,275 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $37.2K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Advisors Asset Management's portfolio in Q3 2026, its #1385 holding.
  • Advisors Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 8 quarters since.
  • Advisors Asset Management's MoonLake Immunotherapeutics position peaked at $189K in Q2 2025.
  • 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Advisors Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.